Study identifier:D2340C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD5423 after Administration of Single and Multiple Ascending Doses in Healthy Male Japanese Subjects
Healthy
Phase 1
Yes
AZD5423, Placebo
Male
96
Interventional
20 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: AZD5423 Inhalation, suspension |
Placebo Comparator: 2 | Drug: Placebo Inhalation, solution |